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In the recently published update of the European Society of
Cardiology/European Atherosclerosis Society (ESC/EAS) clinical prac-
tice guidelines for the management of dyslipidaemias, indications for
lipid-lowering treatment have been expanded to those at lower cardi-
ovascular risk and with lower LDL levels, as well as to those 65–75
years of age, according to their level of predicted cardiovascular disease
(CVD) risk [1,2]. To what extent these updates affect treatment re-
commendations at population level is unclear.
1. Methods
We compared the implications of the 2016 and 2019 ESC/EAS
guidelines in 7262 participants free of CVD, aged 45–75 years, from the
Dutch prospective population-based Rotterdam Study. Details re-
garding the study design, measurements and follow-up have been de-
scribed in detail previously [3–5].
We calculated 10-year risk of CVD mortality following the 2016 and
2019 ESC/EAS guidelines using sex-specific Systematic Coronary Risk
Evaluation (SCORE) equations for low-risk countries, and subsequently
classified individuals based on whether they would qualify for lipid-
lowering treatment. Treatment categories were defined as per ESC/EAS
guideline recommendations as either: (1) no treatment – provide life-
style advice, (2) treatment considered – provide lifestyle intervention,
consider adding drug, and (3) treatment recommended – provide life-
style intervention and concomitant drug intervention.
2. Results
Mean (SD) age was 61.1 (6.9) years and 58.2% were women.
Diabetes was present in 8.4% of the participants, 24.7% were smokers,
mean LDL was 3.7 (0.9) mmol/L, and mean blood pressure was 137/80
(20/11) mmHg.
Besides lifestyle interventions, the 2016 and 2019 ESC/EAS guide-
lines recommend statin treatment in 13.2% (N = 961) and 37.7%
(N = 2738) of the population, and consider statin treatment for an
additional 37.0% (N = 2689) and 51.4% (N = 3733), respectively.
When stratified by 5-year age groups, the proportion of individuals
eligible for statin treatment increases with age for both 2016 and 2019
ESC/EAS guidelines in a similar pattern (Fig. 1). However, the 2016 and
2019 ESC/EAS guidelines overall suggest a respective 29.7% (N = 411)
and 60.7% (N = 839) of adults aged 45–55 years to be considered for
statin treatment if LDL remains uncontrolled after lifestyle interven-
tions. Adults with an estimated 10-year SCORE risk of fatal CVD<1%
and LDL<4.9 mmol/L were deemed to be at sufficiently low risk in the
2016 ESC/EAS guidelines and hence were suggested only lifestyle ad-
vice to modify their cardiovascular risk (evidence class/level: I/C) [2].
In the 2019 update, adults with SCORE risk< 1% and LDL between 3.0
and 4.9 mmol/L should also be considered for statin treatment (IIa/A)
[1]. This led to the consideration of statin treatment in an additional
517 individuals (i.e. 37.4% of 1383 adults aged 45–55 years) in our
study.
The 2016 ESC/EAS guidelines did not provide treatment re-
commendations for individuals aged> 65 years, while the 2019 ESC/
EAS guidelines recommend statin treatment in 69.2% (N = 1430) and
consider treatment in 27.7% (N = 571) among the study population
aged 65–75 years (N = 2065) (Fig. 1).
3. Discussion
The 2019 ESC/EAS dyslipidaemia guidelines expand treatment re-
commendations to asymptomatic adults with SCORE risk< 1% and
LDL cholesterol levels below 4.9 mmol/L, thus deeming an additional
37.4% of all individuals aged 45–55 years to be at sufficient risk to be
considered for statin treatment. This is relevant, as an additional one
third of the middle-aged population should now have a discussion with
their health care provider regarding initiation of statin treatment. The
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updates in the most recent set of guidelines can be supported by evi-
dence that statin treatment reduces risk of hard CVD end points up to
20 years later [6], and that even younger and relatively low-risk in-
dividuals are likely to benefit from long-term statin use [7].
Moreover, following the 2019 ESC/EAS guidelines, 69.2% of
asymptomatic individuals aged 65–75 years are now eligible for statin
treatment in our study, and another 27.7% should be considered for
statin treatment. SCORE has been shown to overestimate risk in adults
over 65 years of age [8], and ESC/EAS guideline makers in 2016 noted
that there was not sufficient evidence at that time to provide re-
commendation for statin treatment for this age group [2]. Nevertheless,
expanding treatment recommendations in the 2019 ESC/EAS update to
adults up to 75 years of age is an important change, supported by recent
meta-analyses of randomized trials demonstrating the benefit of statin
use in a primary prevention setting among older individuals [9].
Whether the broadening of statin indications in asymptomatic low-
risk individuals and those aged 65–75 years will lead to a greater up-
take of primary prevention efforts and thereby a long-term lowering of
the burden of CVD in Europe, remains to be investigated.
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